عرض بسيط للتسجيلة

المؤلفMajbour, Nour K.
المؤلفVaikath, Nishant N.
المؤلفvan Dijk, Karin D.
المؤلفArdah, Mustafa T.
المؤلفVarghese, Shiji
المؤلفVesterager, Louise B.
المؤلفMontezinho, Liliana P.
المؤلفPoole, Stephen
المؤلفSafieh-Garabedian, Bared
المؤلفTokuda, Takahiko
المؤلفTeunissen, Charlotte E.
المؤلفBerendse, Henk W.
المؤلفvan de Berg, Wilma D. J.
المؤلفEl-Agnaf, Omar M. A.
تاريخ الإتاحة2016-11-02T07:14:51Z
تاريخ النشر2016-01-19
اسم المنشورMolecular Neurodegeneration
المعرّفhttp://dx.doi.org/10.1186/s13024-016-0072-9
الاقتباسMajbour NK, Vaikath NN, van Dijk KD, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. Molecular Neurodegeneration. 2016;11:7.
الرقم المعياري الدولي للكتاب1750-1326
معرّف المصادر الموحدhttp://hdl.handle.net/10576/4952
الملخصBackground Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson’s disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach. Results To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer’s disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37). Conclusion Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.
راعي المشروعDutch Parkinson Foundation (Parkinson Vereniging) and Stichting Parkinson Fonds (SPF). Michael J. Fox Foundation for Parkinson’s Research (New York).
اللغةen
الناشرBioMed Central
الموضوعParkinson’s disease
Alpha synuclein
Cerebrospinal fluid biomarkers
Biomarkers
العنوانOligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
النوعArticle
رقم العدد7
رقم المجلد11
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة